CBPO  China Biologic Products Inc.




Health Care


Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.


Vuru Grade


Current Price

+0.06 (+0.09%)

Growth Price

Overvalued by 54.31%

Stability Price

Overvalued by 71.47%

Company Metrics

  • 26.76 P/E
  • 7.35 P/S
  • 8.62 P/B
  • 2.538 EPS
  • 40.69% Cash ROIC
  • 2.38 Cash Ratio
  • 0 / 0% Dividend
  • 75,540.00 Avg. Vol.
  • 1.676B Market Cap.

Company Description

China Biologic Products, Inc., a biopharmaceutical company, engages in the research, development, production, and manufacture of plasma-based pharmaceutical products in the People's Republic of China. It offers Human Albumin for the treatment of shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and...

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Update: China Biologic Products Q3 Earnings Beat (CBPO)
Seeking Alpha (registration) - Nov 6, 2014
Before Q2 earnings on August 5, I wrote a bullish article on China Biologic Products (NASDAQ:CBPO), with a thesis stating that the company's plasma-based products should benefit from increasing market demand in China for Q2. I argued that the company's ...
China Biologic Products Becomes Oversold (CBPO)
Forbes - Oct 13, 2014
In trading on Monday, shares of China Biologic Products Inc (NASD: CBPO) entered into oversold territory, hitting an RSI reading of 29.1, after changing hands as low as $49.11 per share.
China Biologic Products Earnings Preview (CBPO)
Seeking Alpha (registration) - Aug 5, 2014
China Biologic Products (NASDAQ: CBPO), a biopharmaceutical company focused on developing plasma-based products, has been subjected to a roller coaster ride over the last several months. Back in mid June, shares fell more than 11% after the ...
China Biologic Products Stock Rating Upgraded by Zacks (CBPO)
Dakota Financial News - Jan 27, 2015
China Biologic Products has a 52-week low of $27.34 and a 52-week high of $71.27. The stock's 50-day moving average is $66.36 and its 200-day moving average is $57.3.
Brokerage Firm Price Target on China Biologic Products Inc
Stafford Daily - Jan 23, 2015
Equity Analysts at the Jefferies maintains the rating on China Biologic Products Inc (NASDAQ:CBPO). The brokerage firm has issued a Buy rating on the shares.
China Biologic to Build Two New Plasma Collection Stations in Hebei Province
PR Newswire (press release) - Nov 3, 2014
BEIJING, Nov. 3, 2014 /PRNewswire/ -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its majority-owned subsidiary ...
Why China Biologic Products (CBPO) Could Be an Impressive Growth Stock
Zacks.com - Aug 19, 2014
One such company that might be well-positioned for future earnings growth is China Biologic Products, Inc. (CBPO - Snapshot Report).
China Biologic Presents A Unique Investment Opportunity
Seeking Alpha (registration) - Sep 22, 2014
Undoubtedly, both China Biologic's majority stake in Guizhou and its two successive quarters of rising product revenues are healthy signs of a rapidly growing healthcare company. Nevertheless, with such impressive growth and incredible stock ...
China Biologic Products (CBPO) CEO David Gao on Q2 2014 Results - Earnings ...
Seeking Alpha (registration) - Aug 11, 2014
China Biologic Products (CBPO) CEO David Gao on Q2 2014 Results - Earnings Call Transcript. Aug. 10, 2014 10:18 PM ET | About: China Biologic Products, Inc. (CBPO) by: SA Transcripts. China Biologic Products, Inc. (NASDAQ:CBPO). Q2 2014 Earnings ...
Short Interest of China Biologic Products Inc Increases by 11.4%
Ashburn Daily - Jan 21, 2015
China Biologic Products Inc (NASDAQ:CBPO) has witnessed a colossal rise of 11.4% or 2,556 shares in its short figure. The short interest augmentation took it from 22,351 on December 15,2014 to 24,907 on December 31,2014.